STOCK TITAN

Guardant Health - GH STOCK NEWS

Welcome to our dedicated page for Guardant Health news (Ticker: GH), a resource for investors and traders seeking the latest updates and insights on Guardant Health stock.

Overview of Guardant Health

Guardant Health is a precision oncology company that specializes in liquid biopsy tests and advanced genomic diagnostics. As a leader in the field of liquid biopsy and cancer diagnostics, the company has developed innovative, non-invasive tools that enable oncologists to access and sequence tumor DNA, thereby providing critical insights into cancer biology. Its robust suite of tests is designed for various clinical applications including treatment selection, detection of minimal residual disease, and broader gene panel analyses for immuno-oncology research.

Core Business Areas

Guardant Health operates at the intersection of advanced technology and medical science to revolutionize the way cancer is diagnosed and monitored. The company offers a comprehensive range of services, including:

  • Liquid Biopsy Testing: Non-invasive blood tests that analyze circulating tumor DNA to inform treatment decisions and monitor disease progression.
  • Companion Diagnostics: FDA-approved assays that help guide targeted cancer therapies ensuring that patients receive tailored treatment options.
  • Molecular Residual Disease (MRD) Testing: Tumor-agnostic tests designed to detect molecular evidence of cancer recurrence, enhancing post-treatment monitoring.
  • Research and Development Services: End-to-end support in regulatory consultancy and clinical trial referral, aiding clinical research and collaboration.

Market Position and Industry Impact

Guardant Health has established a significant presence in the precision oncology landscape by harnessing advanced data analytics and genomics. Its liquid biopsy solutions provide a safer, more efficient alternative to traditional tissue biopsies, thus facilitating faster and more accurate diagnostic processes. The company is also known for contributing to the broadening of cancer data acquisition, a crucial factor in driving discovery and innovation in cancer treatment and research. The integration of real-world data with artificial intelligence analytics has positioned Guardant Health as a valuable partner in both clinical and research settings, offering insights that have the potential to influence treatment protocols and clinical guidelines.

Operational Excellence and Scientific Rigor

At the core of Guardant Health's operations is a rigorous dedication to scientific accuracy and clinical validation. Every test is backed by detailed research and validated methodologies that ensure precise outcomes. The company emphasizes a strong ethical foundation by ensuring that its products are developed with a focus on patient safety and diagnostic integrity. This approach not only enhances trust among clinicians but also positions the firm as an authoritative voice in the field of oncology diagnostics.

Competitive Landscape and Differentiation

In a competitive market where several companies vie to innovate in cancer diagnostics, Guardant Health differentiates itself through its comprehensive approach to liquid biopsy technology. The company’s ability to offer a spectrum of tests across various stages of cancer care—ranging from early detection to monitoring minimal residual disease—illustrates its commitment to improving patient outcomes. Additionally, its successful legal defenses and insistence on data accuracy further underscore its focus on maintaining high standards across all areas of operation.

Commitment to Innovation and Data-Driven Discoveries

Guardant Health’s approach is deeply rooted in the belief that conquering cancer is as much a data problem as it is a medical challenge. Through the creation and application of advanced sequencing techniques and comprehensive data analytics, the company is continuously expanding its product offerings and clinical insights. This data-centric approach not only fuels ongoing innovation but also supports extensive research collaborations that are pivotal for furthering advancements in cancer care.

Conclusion

Overall, Guardant Health represents a forward-thinking enterprise in the realm of precision oncology, offering groundbreaking diagnostic solutions that bridge the gap between advanced technology and clinical practice. Its commitment to non-invasive testing, rigorous validation, and comprehensive clinical services helps demystify the complexities of cancer diagnostics, making it an essential component of modern medical research and patient care.

Rhea-AI Summary

Guardant Health (Nasdaq: GH) has submitted the final module of its premarket approval (PMA) application for the Shield™ blood test designed to screen for colorectal cancer (CRC) to the U.S. Food and Drug Administration (FDA). This application includes data from the ECLIPSE study, which involved over 20,000 patients, indicating an 83% sensitivity and 90% specificity for detecting CRC. Launched in May 2022, the Shield test has shown approximately 90% adherence in real-world scenarios. Guardant aims to enhance cancer screening access, especially in underserved populations, as CRC remains the second leading cause of cancer-related deaths.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.16%
Tags
none
-
Rhea-AI Summary

Guardant Health, Inc. (NASDAQ: GH) has appointed Musa Tariq to its board of directors, effective March 6. Tariq, currently the CMO of GoFundMe, brings extensive marketing experience from global brands like Airbnb and Ford. His expertise is expected to enhance Guardant's brand and mission to improve cancer detection and patient outcomes. The company focuses on precision oncology, with products like Guardant360 and Guardant Reveal for cancer monitoring and screening. Tariq's addition comes at a crucial time as Guardant continues to advance its innovative offerings in the oncology field.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.78%
Tags
management
-
Rhea-AI Summary

Guardant Health reported a strong performance in Q4 2022, achieving $126.9 million in revenue, a 17% increase year-over-year. The company conducted 36,000 tests for clinical customers and 8,200 tests for biopharmaceutical clients, corresponding to growth of 41% and 24%, respectively. For the full year, revenue reached $449.5 million, marking a 20% increase. Despite these gains, the net loss for Q4 2022 was $139.9 million, up from $90.9 million in Q4 2021. Looking ahead, Guardant expects 2023 revenue between $525 million to $540 million, signifying an anticipated growth of 17% to 20%.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.68%
Tags
Rhea-AI Summary

Guardant Health, a leader in precision oncology, will participate in two upcoming investor conferences. The first is the Citi 2023 Healthcare Services, MedTech, Tools & HCIT Conference in New York City on March 1, 2023, at 3:30 p.m. Eastern Time. The second is the Cowen 43rd Annual Health Care Conference in Boston on March 8, 2023, at 10:30 a.m. Eastern Time. Live and archived webcasts of both presentations will be available on the Guardant Health website. The company aims to improve cancer care through advanced analytics and proprietary tests like Guardant360 and Shield.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.84%
Tags
conferences
-
Rhea-AI Summary

Guardant Health (NASDAQ: GH) has initiated a new study, Understanding Patient Preference on Colorectal Cancer Screening Options (U-Screen), to evaluate its Shield blood test's effectiveness in improving adherence to colorectal cancer (CRC) screenings among underserved populations. The study targets patients at Federally Qualified Health Centers (FQHC) who have not completed guideline-recommended screenings. The Shield test, which detects CRC via circulating tumor DNA, showed 83% sensitivity and approximately 90% adherence in real-world use. The research aims to address the significant barriers to CRC screening, particularly in minority groups.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.76%
Tags
none
-
Rhea-AI Summary

Guardant Health (NASDAQ: GH) has announced that UnitedHealthcare (UHC) now covers the Guardant360 CDx liquid biopsy test for all FDA-approved indications in advanced or metastatic breast and non-small cell lung cancer (NSCLC) patients. This marks a significant expansion of the test's accessibility, making it available under UHC's commercial policies for enrolled patients. Guardant360 CDx is the first FDA-approved blood test for comprehensive genomic profiling in solid tumors and has been instrumental in matching patients with targeted therapies. With over 250,000 tests performed, its coverage by the largest U.S. national health insurer enhances patient access to critical genomic profiling.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.24%
Tags
none
Rhea-AI Summary

Guardant Health and AnHeart Therapeutics announced a strategic collaboration focused on developing Guardant360 CDx and Guardant360 TissueNext assays as companion diagnostics for taletrectinib, an investigational ROS1 inhibitor targeting advanced non-small cell lung cancer (NSCLC). This partnership aims to expedite regulatory approval and improve patient access to advanced diagnostic tools. Taletrectinib has received FDA Breakthrough Therapy Designation for ROS1-positive NSCLC patients. The collaboration will utilize comprehensive genomic profiling to identify suitable patients for this therapy, enhancing treatment outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.19%
Tags
none
-
Rhea-AI Summary

Guardant Health, Inc. (Nasdaq: GH) announced a favorable recommendation from U.S. District Court Magistrate Judge Christopher J. Burke regarding Illumina's lawsuit filed on March 17, 2022. The judge recommended that nearly all of Illumina's claims be dismissed, affirming Guardant's belief in the validity of its patent ownership. This dismissal is viewed as a significant step in Guardant's mission to enhance cancer care. Guardant Health continues to advance its precision oncology platform with various proprietary tests aimed at improving patient outcomes and reducing healthcare costs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.19%
Tags
none
-
Rhea-AI Summary

Guardant Health (NASDAQ: GH) is set to report its financial results for the fourth quarter and full year 2022 after market close on February 23, 2023. The corresponding conference call will start at 1:30 p.m. PT (4:30 p.m. ET). Listeners can access the live webcast and subsequent archive in the Investors section of the company’s website.

Guardant Health specializes in precision oncology, providing proprietary tests and advanced analytics aimed at improving cancer treatment outcomes and reducing healthcare costs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.19%
Tags
conferences earnings
Rhea-AI Summary

Guardant Health (NASDAQ: GH) has unveiled Guardant Galaxy, a suite of AI-powered analytical technologies aimed at enhancing cancer testing and drug discovery. The first application, developed in collaboration with Lunit, improves biomarker detection by over 20% for the Guardant360 TissueNext PD-L1 test in non-small cell lung cancer cases. Future applications will focus on deep learning-driven genomic and epigenomic discovery, leveraging real-world clinical data from the GuardantINFORM platform. The initiative aims to provide oncologists with precise information and to accelerate biomarker discovery.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.81%
Tags
none

FAQ

What is the current stock price of Guardant Health (GH)?

The current stock price of Guardant Health (GH) is $42.47 as of April 1, 2025.

What is the market cap of Guardant Health (GH)?

The market cap of Guardant Health (GH) is approximately 5.2B.

What is Guardant Health's primary business focus?

Guardant Health specializes in developing and offering liquid biopsy tests for cancer diagnostics, utilizing advanced genomic testing and data analytics to support treatment selection and disease monitoring.

How do Guardant Health's liquid biopsy tests work?

The tests use a non-invasive method to analyze circulating tumor DNA from blood samples, providing oncologists with critical information that can guide treatment decisions and monitor disease progression.

What types of diagnostic assays does Guardant Health offer?

Guardant Health provides a range of assays including companion diagnostics for targeted therapies, molecular residual disease tests for post-treatment monitoring, and extensive gene panels for immuno-oncology research.

How does Guardant Health differentiate itself from competitors?

The company differentiates itself through a comprehensive portfolio of liquid biopsy tests, a strong commitment to scientific rigor, and successful legal defenses that validate its clinical and technological approaches.

What role does data analytics play in Guardant Health’s operations?

Data analytics is fundamental to its approach, enabling the company to harness vast amounts of cancer-related data to drive insights, support clinical decision-making, and fuel ongoing innovations in diagnostic testing.

Who are the primary users of Guardant Health's products?

Guardant Health's products are widely used by oncologists and clinical researchers, serving patients across all cancer stages through both diagnostic support and research collaboration.

What are the benefits of using a liquid biopsy?

Liquid biopsies offer a less invasive alternative to traditional tissue biopsies, reducing patient risk while providing rapid, accurate insights into tumor genetics and disease progression.

How does Guardant Health contribute to advancements in cancer research?

By integrating comprehensive cancer data acquisition with advanced genomic analysis, Guardant Health supports broad research collaborations that drive the discovery of new biomarkers and innovative therapeutic approaches.
Guardant Health

Nasdaq:GH

GH Rankings

GH Stock Data

5.25B
117.50M
4.71%
98.48%
6.4%
Diagnostics & Research
Services-medical Laboratories
Link
United States
PALO ALTO